Figure 1.
Cryptolepine treatment inhibits the viability and growth of melanoma cells. (a) Treatment of melanoma cells (A375, SK-Mel28, SK-Mel119 and Hs294t) and normal human epidermal melanocytes with cryptolepine (0, 1.0, 2.5, 5.0 and 7.5 µM) for 24 or 48 h inhibits cell viability in a dose- and time-dependent manner. Cell viability was determined using an MTT assay as described in the Materials and Methods. Cells were seeded in 96-well plates in 6 replicates/sample and per treatment group. Cells treated with DMSO alone served as a vehicle control. Statistical significance versus control group, *P < 0.05, ¶ P < 0.01, † P < 0.001. (b) Effect of cryptolepine on the colony forming capacity of melanoma cells. Colonies were detected by staining with crystal violet and plates were scanned for photographs. Colonies appear blue-violet.